#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	7092	16S	1529	1529	100.0	16S.l15.c4.ctg.1	1889	612.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1368	1368	C	780	C,A	424,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	13132	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3489	600.3	0	.	n	.	0	T695C	SNP	695	695	T	973	973	C	752	C,A	409,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	13132	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3489	600.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1615	1615	A	669	A,G	366,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	13132	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3489	600.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2249	2249	C	602	C	331	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	13132	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3489	600.3	1	SNP	n	A2045G	1	A2045G	SNP	2045	2045	A	2323	2323	G	627	G,T	351,2	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	13132	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3489	600.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	2875	2875	C	667	C,T	388,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	27	49214	blaTEM	861	861	100.0	blaTEM.l15.c4.ctg.1	1295	5390.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	394	folP	855	855	99.88	folP.l15.c4.ctg.1	1365	47.9	1	SNP	p	R229S	1	.	.	685	687	AGC	847	849	AGC	70;70;70	A;G;C	39;39;41	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_G_01105	gyrA.WHO_G_01105	1	1	539	1324	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3124	70.7	0	.	p	.	0	D95A	NONSYN	283	285	GAC	443	445	GCC	91;91;91	G;C;C	50;52;53	.	.
gyrA.WHO_G_01105	gyrA.WHO_G_01105	1	1	539	1324	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3124	70.7	0	.	p	.	0	L775P	NONSYN	2323	2325	CTG	2483	2485	CCG	16;15;15	C;C,T;G	7;0,5;8	.	.
gyrA.WHO_G_01105	gyrA.WHO_G_01105	1	1	539	1324	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3124	70.7	1	SNP	p	S91F	1	.	.	271	273	TTC	431	433	TTC	87;87;87	T;T;C,G	50;49;50,1	gyrA.WHO_G_01105:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	356	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1229	50.1	1	SNP	p	G45D	0	.	.	133	135	GGC	382	384	GGC	92;92;90	G;G;C	49;49;50	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	242	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	1040	36.6	0	.	n	.	0	A197.	DEL	197	197	A	646	646	A	94	A	53	.	.
parC.WHO_L_00611c	parC.WHO_L_00611c	1	1	27	1148	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2916	65.3	1	SNP	p	S87I	0	.	.	259	261	AGT	501	503	AGT	103;104;105	A;G;T	56;58;59	parC.WHO_L_00611c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_L_00611c	parC.WHO_L_00611c	1	1	27	1148	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2916	65.3	1	SNP	p	S87W	0	.	.	259	261	AGT	501	503	AGT	103;104;105	A;G;T	56;58;59	parC.WHO_L_00611c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_L_00611c	parC.WHO_L_00611c	1	1	27	1148	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2916	65.3	1	SNP	p	S87R	0	.	.	259	261	AGT	501	503	AGT	103;104;105	A;G;T	56;58;59	parC.WHO_L_00611c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	527	920	parE	1986	1986	99.95	parE.l6.c4.ctg.1	2316	65.7	0	.	p	.	0	P456S	NONSYN	1366	1368	CCC	1531	1533	TCC	52;54;52	T;C;C	33;34;33	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	527	920	parE	1986	1986	99.95	parE.l6.c4.ctg.1	2316	65.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1393	1395	GGC	52;52;52	G;G;C	31;29;30	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	527	920	parE	1986	143	96.5	parE.l6.c4.ctg.2	496	1.0	0	.	p	.	0	L523W	NONSYN	1567	1569	CTG	359	361	TGG	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	527	920	parE	1986	143	96.5	parE.l6.c4.ctg.2	496	1.0	0	.	p	.	0	T525P	NONSYN	1573	1575	ACC	365	367	CCC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	527	920	parE	1986	143	96.5	parE.l6.c4.ctg.2	496	1.0	0	.	p	.	0	Y528S	NONSYN	1582	1584	TAC	374	376	TCC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
penA.2.002	penA.2.002	1	1	27	1300	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2054	99.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1092	1094	GCA	157;158;160	G,T;C;A,T	88,1;90;91,1	penA.2.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1300	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2054	99.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1095	1097	ATC	161;161;161	A;T;C	92;91;91	penA.2.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1300	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2054	99.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1107	1109	GTG	165;165;166	G;T;G	93;88;90	penA.2.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1300	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2054	99.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1107	1109	GTG	165;165;166	G;T;G	93;88;90	penA.2.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1300	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2054	99.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1611	1613	ACC	82;84;84	A;C;C	44;49;50	penA.2.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1300	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2054	99.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1665	1667	GCG	73;72;72	G;C;G	50;48;45	penA.2.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1300	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2054	99.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1665	1667	GCG	73;72;72	G;C;G	50;48;45	penA.2.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1300	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2054	99.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1788	1790	GGC	54;56;56	G;G;C	35;36;34	penA.2.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1300	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2054	99.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1797	1799	GGC	49;49;47	G;G;C	34;33;22	penA.2.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1300	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2054	99.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1815	1817	CCG	53;51;50	C,G;C;G	29,1;27;26	penA.2.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	2380	ponA	2397	2397	100.0	ponA.l15.c17.ctg.1	2861	128.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1544	1546	CCG	59;60;63	C;C;G	28;32;33	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	612	porA	1146	1146	99.83	porA.l15.c17.ctg.1	1655	61.4	0	.	p	.	0	S22G	NONSYN	64	66	AGC	229	231	GGC	72;72;72	G;G;C	39;40;39	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	612	porA	1146	1146	99.83	porA.l15.c17.ctg.1	1655	61.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	411	411	C	35	C	20	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	926	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	1440	96.8	1	SNP	p	G120K	1	G120K	NONSYN	358	360	GGC	456	458	AAG	93;93;95	A;A;G	53;51;52	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	926	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	1440	96.8	0	.	p	.	0	D121G	NONSYN	361	363	GAC	459	461	GGC	95;95;97	G;G;C	54;54;54	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	926	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	1440	96.8	0	.	p	.	0	E212D	NONSYN	634	636	GAA	732	734	GAT	214;216;216	G;A;T	122;121;121	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	926	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	1440	96.8	0	.	p	.	0	H213G	NONSYN	637	639	CAT	735	737	GGT	213;214;213	G;G,A;T	119;121,1;118	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	926	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	1440	96.8	0	.	p	.	0	V215A	NONSYN	643	645	GTT	741	743	GCT	218;218;218	G,A;C;T	123,1;126;124	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	926	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	1440	96.8	0	.	p	.	0	I218M	NONSYN	652	654	ATC	750	752	ATG	166;164;166	A;T;G	94;91;90	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	926	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	1440	96.8	0	.	p	.	0	R257T	NONSYN	769	771	AGG	867	869	ACG	86;86;86	A;C;G	46;49;51	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	926	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	1440	96.8	0	.	p	.	0	A259V	NONSYN	775	777	GCT	873	875	GTT	81;81;81	G;T,G;T	44;45,1;47	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	926	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	1440	96.8	0	.	p	.	0	D297N	NONSYN	889	891	GAC	987	989	AAC	95;94;97	A;A;C	50;51;51	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	3584	rpoB	4179	4179	99.95	rpoB.l15.c4.ctg.1	4643	128.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	344	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	656	92.3	1	SNP	p	V57M	1	.	.	169	171	ATG	362	364	ATG	116;114;118	A;T;G	68;65;68	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
tetM.WHO_G_pTetM_00047	tetM.WHO_G_pTetM_00047	1	0	27	7100	tetM	1920	1920	100.0	tetM.l15.c4.ctg.1	2202	489.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Tetracycline resistance
